We are studying a new treatment, called Solenazumab, for Alzheimer’s disease. Solenazumab is given through intravenous injections and acts by attaching to proteins associated with the disease and preventing them from gathering in the brain. We are examining whether Solenazumab will safely and effectively slow the progression of Alzheimer’s disease, analyzing how the drug is processed by the body, and evaluating whether it will act differently across people.
Aims: Will solanezumab continue to slow the rate of mental (thinking and remembering) decline of Alzheimer’s disease as compared to placebo? How safe is solanezumab and what side effects might be associated with it? Current status: Project live
Primary Investigator: David Sultzer
